Enzymatic Clearance of Excess Free Cholesterol Reduces NASH Pathology in Models of Disease

Time: 10:00 am
day: Conference Day 1


  • Excess intracellular free cholesterol is hypothesized to drive NASH pathology
  • Developing a LNP-mRNA therapy that expresses a cholesterol-degrading fusion protein in the liver
  • 4 to 8 weeks of weekly dosing with the Repair Biotechnologies therapy significantly reduces NASH associated biomarkers and histology in mouse models of disease